Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents
作者:Imadul Islam、Edward B. Skibo、Robert T. Dorr、David S. Alberts
DOI:10.1021/jm00114a003
日期:1991.10
Described herein are structure-activity studies of new antitumor agents based on the pyrrolo[1,2-a]benzimidazole (PBI) ring system. These compounds were designed as new DNA cross-linkers mimicking the mitomycin antitumor agents. Actually, the PBI derivatives were found to have anthracycline-like features: (i) shared cross resistance with doxorubicin in a human myeloma line, (ii) cardiotoxicity, and
本文描述了基于吡咯并[1,2-a]苯并咪唑(PBI)环系统的新型抗肿瘤药的结构活性研究。这些化合物被设计为模仿丝裂霉素抗肿瘤剂的新的DNA交联剂。实际上,发现PBI衍生物具有类似蒽环类的特征:(i)在人骨髓瘤细胞系中与阿霉素共有交叉耐药性,(ii)心脏毒性,以及(iii)优异的DNA链切割能力。DNA链的断裂被认为是由于DNA的还原性烷基化,随后是活性氧自由基的产生。研究的最佳抗肿瘤药物是6-N-叠氮基-3-羟基-7-甲基-2,3-二氢-1H-吡咯并-[1,2-a]苯并咪唑-5,8-二酮3-乙酸盐(PBI- A),其具有针对各种人类卵巢癌和结肠癌细胞系的纳摩尔IC50值。